Our Science

Publications and Presentations

March 2021
March 2021
A Second-Generation Fungerp Analog, SCY-247, Shows Potent In Vitro Activity against Candida auris and Other Clinically Relevant Fungal Isolates Antimicrobial Agents and Chemotherapy Sherman Chu,a,b Lisa Long,a,d Rania Sherif,a,d Thomas S. McCormick,a Katyna Borroto-Esoda,c Stephen Barat,cMahmoud A. Ghannouma,d
October 2020
Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI) BD Alexander, OA Cornely, PG Pappas, R Miller, M Johnson, J Vazquez, L Ostrosky-Zeichner, A Spec, R Rautemaa-Richardson, R Krause, GR Thompson, TJ Walsh, CG Morse, JW Sanders, D Andes, GM Lyon, FM Marty, MH Miceli, TF Patterson, M Hoenigl, N Azie, DA Angulo
ID Week
June 2020
Determination of Antifungal Activity of SCY-078, a Novel Glucan Synthase Inhibitor, Against a broad panel of Rare Pathogenic Fungi M. Ghannoum, L. Long, R. Sherif, F. Z. Abidi, K. Borroto-Esoda, S. Barat, D. Angulo, N. Wiederhold
ASM Microbe Online
June 2020
Delayed Initiation of the Novel Oral Glucan Synthase Inhibitor, Ibrexafungerp, is Effective in a Murine Model of Invasive Candidiasis caused by Candida auris N.P. Wiederhold, L.K. Najvar, R. Jaramillo, M. Olivo, H. Patterson, S. Barat, K. Borroto-Esoda, G. Catano, T.F. Patterson
UT Health San Antonio, South Texas Veterans Health Care System, SCYNEXIS, Inc.
ASM Microbe Online
April 2020
Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model Stephen Barat, Katyna Borroto-Esoda, Alan Ashbaugh, Melanie Cushion